Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Peter Kremsner; Philipp Mann; Jacobus Bosch; Rolf Fendel; Julian J. Gabor; Andrea Kreidenweiss; Arne Kroidl; Isabel Leroux-Roels; Geert Leroux-Roels; Christoph Schindler; Mirjam Schunk; Thirumalaisamy P. Velavan; Mariola Fotin-Mleczek; Stefan Müller; Gianluca Quintini; Oliver Schönborn-Kellenberger; Dominik Vahrenhorst; Thomas Verstraeten; Lisa Walz; Olaf-Oliver Wolz; Lidia Oostvogels

doi:10.1101/2020.11.09.20228551

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Peter Kremsner, Philipp Mann, Jacobus Bosch, Rolf Fendel, Julian J. Gabor, Andrea Kreidenweiss, Arne Kroidl, Isabel Leroux-Roels, Geert Leroux-Roels, Christoph Schindler, Mirjam Schunk, Thirumalaisamy P. Velavan, Mariola Fotin-Mleczek, Stefan Müller, Gianluca Quintini, Oliver Schönborn-Kellenberger, Dominik Vahrenhorst, Thomas Verstraeten, Lisa Walz, Olaf-Oliver Wolz, Lidia Oostvogels

doi: https://doi.org/10.1101/2020.11.09.20228551

Peter Kremsner

1Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany

10German Center for Infection Research (DZIF), partner site Tübingen, Tübingen, Germany

11Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Philipp Mann

6Curevac AG, Frankfurt, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jacobus Bosch

5Hannover Medical School (MHH), Hannover, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Rolf Fendel

1Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Julian J. Gabor

1Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andrea Kreidenweiss

1Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Arne Kroidl

3Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Germany

4German Center for Infection Research (DZIF), partner site Munich, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Isabel Leroux-Roels

2Ghent University Hospital, Ghent, Belgium

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Geert Leroux-Roels

2Ghent University Hospital, Ghent, Belgium

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christoph Schindler

5Hannover Medical School (MHH), Hannover, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mirjam Schunk

3Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Germany

4German Center for Infection Research (DZIF), partner site Munich, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thirumalaisamy P. Velavan

1Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mariola Fotin-Mleczek

9Curevac AG, Tübingen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Stefan Müller

6Curevac AG, Frankfurt, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gianluca Quintini

8Cogitars, Heidelberg, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Oliver Schönborn-Kellenberger

8Cogitars, Heidelberg, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Dominik Vahrenhorst

9Curevac AG, Tübingen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thomas Verstraeten

7P95 Epidemiology and Pharmacovigilance, Leuven, Belgium

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lisa Walz

6Curevac AG, Frankfurt, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Olaf-Oliver Wolz

9Curevac AG, Tübingen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lidia Oostvogels

6Curevac AG, Frankfurt, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: lidia.oostvogels@curevac.com

Abstract
Full Text
Info/History
Metrics
Supplementary material
Data/Code
Preview PDF

Data Availability

No additional data are referred to

View the discussion thread.

PreviousNext

Posted November 09, 2020.

Download PDF

Supplementary Material

Data/Code

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Message Subject (Your Name) has forwarded a page to you from medRxiv

Message Body (Your Name) thought you would like to see this page from the medRxiv website.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

medRxiv 2020.11.09.20228551; doi: https://doi.org/10.1101/2020.11.09.20228551

Share This Article:

Citation Tools

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

medRxiv 2020.11.09.20228551; doi: https://doi.org/10.1101/2020.11.09.20228551

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Tweet Widget
Facebook Like
Google Plus One

Subject Area

Infectious Diseases (except HIV/AIDS)

Subject Areas

All Articles

Addiction Medicine (70)
Allergy and Immunology (168)
Anesthesia (50)
Cardiovascular Medicine (450)
Dentistry and Oral Medicine (82)
Dermatology (55)
Emergency Medicine (157)
Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
Epidemiology (5248)
Forensic Medicine (3)
Gastroenterology (195)
Genetic and Genomic Medicine (755)
Geriatric Medicine (80)
Health Economics (212)
Health Informatics (696)
Health Policy (356)
Health Systems and Quality Improvement (223)
Hematology (99)
HIV/AIDS (162)
Infectious Diseases (except HIV/AIDS) (5848)
Intensive Care and Critical Care Medicine (358)
Medical Education (103)
Medical Ethics (25)
Nephrology (80)
Neurology (762)
Nursing (43)
Nutrition (130)
Obstetrics and Gynecology (141)
Occupational and Environmental Health (231)
Oncology (476)
Ophthalmology (150)
Orthopedics (38)
Otolaryngology (95)
Pain Medicine (39)
Palliative Medicine (20)
Pathology (140)
Pediatrics (223)
Pharmacology and Therapeutics (136)
Primary Care Research (96)
Psychiatry and Clinical Psychology (859)
Public and Global Health (2004)
Radiology and Imaging (348)
Rehabilitation Medicine and Physical Therapy (158)
Respiratory Medicine (283)
Rheumatology (94)
Sexual and Reproductive Health (73)
Sports Medicine (76)
Surgery (109)
Toxicology (25)
Transplantation (29)
Urology (39)